Answers are grounded in this paper and cite their sources.
Administration of vaccine for hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for patients with chronic hepatitis C (CHC) because of the potential for increased severity of acute hepatitis superimposed on existing liver disease. The aim of this study is to determine the prevalence of antibodies directed against HAV and HBV in patients with CHC, analyze demographic and risk factors associated with this prevalence, and develop a cost-effective vaccination strategy.
No takes yet. Share an insight, caveat, or question.
Mutchnick et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: